- RGLS has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $83.9 million.
- RGLS is up 2.4% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in RGLS with the Ticky from Trade-Ideas. See the FREE profile for RGLS NOW at Trade-Ideas More details on RGLS: Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. Currently there are 3 analysts that rate Regulus Therapeutics a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Regulus Therapeutics has been 1.2 million shares per day over the past 30 days. Regulus has a market cap of $823.6 million and is part of the health care sector and drugs industry. The stock has a beta of 1.79 and a short float of 10.9% with 0.36 days to cover. Shares are up 166% year-to-date as of the close of trading on Thursday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.